A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
147 participants
Dec 5, 2019
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to observe and evaluate the efficacy and safety of multiple drug combinations in the treatment of advanced esophageal squamous cell carcinoma.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Apatinib 250mg, q.d.po+SHR-1210(Camrelizumab)200 mg,Intravenous injection,q2W
Apatinib 250mg, q.d.po+SHR-1316(Adebrelimab) 1200 mg,Intravenous injection,q2W
SHR-1316 was administered intravenously, 1200mg, Q3W; SHR-A2009 8mg/kg, iv, Q3W,
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT03736863